U.S. markets close in 56 minutes

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.33-1.56 (-2.79%)
As of 03:03PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close55.89
Bid53.13 x 800
Ask53.53 x 800
Day's Range52.33 - 55.96
52 Week Range52.33 - 142.62
Avg. Volume169,461
Market Cap928.886M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-14.65
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est174.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MDGL

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Madrigal Pharmaceuticals, Inc.
    Analyst Report: Abbott LaboratoriesAbbott Laboratories is a diversified healthcare company that develops, manufactures and markets a wide range of medical products and services. Its main product lines are nutritionals for adults and infants, diagnostic systems, vascular implants, cardiac rhythm management products, and diabetes care products.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

    CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer. “We are pleased to welcome Dr. Labriola to Madrigal at this pivotal time for the company,” said Becky Taub, M.D., President R&D and CMO of Madrigal. “With 35 years of experienc

  • American City Business Journals

    Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M

    Philadelphia-area life sciences news this week includes updates on a company seeking a patent for its Covid-19 therapy, a private stock sale, and a Temple University spinout publishing its study findings on a potential treatment for NASH.

  • Motley Fool

    3 Biotech Stocks With Major Catalysts in January

    Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.